Targeted Genetics Corporation (Nasdaq:TGEN) and its scientific collaborators at The Children’s Hospital of Philadelphia and Columbus Children’s Research Institute (CCRI) today announced that the National Institute of Allergy and Infectious Disease (NIAID) has awarded a $21.75 million contract to expand AAV-based HIV vaccine development. This contract is being supported by the HIV Vaccine Design and Development Teams (HVDDT) program from the NIAID Division of AIDS. Under the terms of this agreement, Targeted Genetics as a subcontractor is eligible to receive up to $18 million of the total over 5 years to be used to advance AAV-based vaccines against HIV.
